ATNM (actiniumpharma.com) Enterprise Value-to-Revenue Coefficient

Public company logo of Actinium Pharma (ATNM)

By leveraging a network of local laboratories in the US, Actinium Pharmaceuticals (ATNM) ensures ultra-fast delivery of short-lived isotopes. An academic approach and R&D budgets enable the company to attract leading oncologists to develop leukemia therapies. The company's price-to-sales ratio on this GURU.Markets chart is recorded at 175.14, confirming the value of "smart bombs"—innovations that destroy blood cancer cells without damaging organs.

ATNM actiniumpharma.com: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Actinium Pharma (ATNM)

- market value and analyst target forecast:
- money and cash flow information:
Initial company analysis:Actinium Pharmaceuticals
Original product of Actinium Pharmaceuticals, Inc.

For the biopharmaceutical sector, given the high dependence of Actinium Pharmaceuticals (ATNM) on external nuclear capacities and CMOs, this indicator serves as a tool for assessing the business's market attractiveness. By analyzing the enterprise value-to-revenue ratio, an investor compares the total enterprise value minus net debt against sales volume, which allows for the identification of asset overvaluation considering its capital-intensive outsourcing.